A. Dimitrios Colevas

Medical oncologist

Head and neck specialist, Otolaryngologist

Head and Neck Cancer Program

  • 900 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Residency: Johns Hopkins School of Medicine (1992) MD

Internship: Johns Hopkins School of Medicine (1990) MD

Board Certification: Medical Oncology, American Board of Internal Medicine (1995)

Fellowship: Dana-Farber Cancer Institute (1995) MA

Medical Education: Johns Hopkins School of Medicine (1989) MD

B. A., Columbia, Chemistry (1985)

M.D., Johns Hopkins, Medicine (1989)

Targeting CD137 enhances the efficacy of cetuximab.
Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., & Levy, R. (2014). Targeting CD137 enhances the efficacy of cetuximab. journal of clinical investigation, 124(6), 2668-2682.

Targeting CD137 enhances the efficacy of cetuximab.
Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., & Levy, R. (2014). Targeting CD137 enhances the efficacy of cetuximab. journal of clinical investigation, 124(6), 2668-2682.

Long-term outcomes of surgery followed by radiation therapy for minor salivary gland carcinomas.
Zeidan, Y. H., Shultz, D. B., Murphy, J. D., An, Y., Chan, C., & Le, Q.-T. (2013). Long-term outcomes of surgery followed by radiation therapy for minor salivary gland carcinomas. Laryngoscope, 123(11), 2675-2680.

Head and Neck Cancers, Version 2.2013 Featured Updates to the NCCN Guidelines
Pfister, D. G., Ang, K.-K., Brizel, D. M., Burtness, B. A., Busse, P. M., & Hughes, M. (2013). Head and Neck Cancers, Version 2.2013 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(8), 917-923.

Stereotactic Radiosurgery for Retreatment of Gross Perineural Invasion in Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck
Tang, C., Fischbein, N. J., Murphy, J. D., Chu, K. P., Bavan, B., & Quynh-Thu Le, Q. T. (2013). Stereotactic Radiosurgery for Retreatment of Gross Perineural Invasion in Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 36(3), 293-298.

Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence
Ho, A. S., Tsao, G. J., Chen, F. W., Shen, T., Kaplan, M. J., & Yao, M. (2013). Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence. CANCER, 119(7), 1349-1356.

Biased View of the Role of Site-Specific Therapy in Carcinoma of Unknown Primary.
Percival, M. E., & Colevas, A. D. (2013). Biased View of the Role of Site-Specific Therapy in Carcinoma of Unknown Primary. Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Population-based evaluation of incidence trends in oropharyngeal cancer focusing on socioeconomic status, sex, and race/ethnicity.
Colevas, A. D. (2013). Population-based evaluation of incidence trends in oropharyngeal cancer focusing on socioeconomic status, sex, and race/ethnicity. Head & neck.

Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential.
LoRusso, P. M., Piha-Paul, S. A., Mita, M., Colevas, A. D., Malhi, V., & Graham, R. A. (2013). Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential. Cancer chemotherapy and pharmacology, 71(1), 193-202.

Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors
Kunz, P. L., He, A. R., Colevas, A. D., Pishvaian, M. J., Hwang, J. J., & Marshall, J. L. (2012). Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors. INVESTIGATIONAL NEW DRUGS, 30(6), 2364-2370.

A Phase 2 Trial of Flavopiridol (Alvocidib) and Cisplatin in Platin-Resistant Ovarian and Primary Peritoneal Carcinoma: MC0261
Bible, K. C., Peethambaram, P. P., Oberg, A. L., Maples, W., Groteluschen, D. L., & Erlichman, C. (2012). A Phase 2 Trial of Flavopiridol (Alvocidib) and Cisplatin in Platin-Resistant Ovarian and Primary Peritoneal Carcinoma: MC0261. GYNECOLOGIC ONCOLOGY, 127(1), 55-62.

Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors
Trakul, N., Chang, C. N., Harris, J., Chapman, C., Rao, A., & Diehn, M. (2012). Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(1), 231-237.

A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
Diaz-Padilla, I., Siu, L. L., San Pedro-Salcedo, M., Razak, A. Ra., Colevas, A. D., & Wakelee, H. A. (2012). A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours. BRITISH JOURNAL OF CANCER, 107(4), 604-611.

Validation that Metabolic Tumor Volume Predicts Outcome in Head-and-Neck Cancer
Tang, C., Murphy, J. D., Khong, B., La, T. H., Kong, C., & Quynh-Thu Le, Q. T. (2012). Validation that Metabolic Tumor Volume Predicts Outcome in Head-and-Neck Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 83(5), 1514-1520.

A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma
Kim, K. B., Prieto, V., Joseph, R. W., Diwan, A. H., Gallick, G. E., & Colevas, A. D. (2012). A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. MELANOMA RESEARCH, 22(4), 294-301.

Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl(+) hematological malignancies
Bose, P., Perkins, E. B., Honeycut, C., Wellons, M. D., Stefan, T., & Grant, S. (2012). Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl(+) hematological malignancies. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 69(6), 1657-1667.

Effect of stimulation of natural killer cells with an anti-CD137 mAb on the efficacy of trastuzumab, cetuximab, and rituximab
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M., Lund, P., & Levy, R. (2012). Effect of stimulation of natural killer cells with an anti-CD137 mAb on the efficacy of trastuzumab, cetuximab, and rituximab. JOURNAL OF CLINICAL ONCOLOGY, 30(15).

ECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP).
Marur, S., Lee, J.-W., Cmelak, A., Zhao, W., Westra, W. H., & Burtness, B. (2012). ECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP). JOURNAL OF CLINICAL ONCOLOGY, 30(15).

Intensity-Modulated Radiotherapy for Tumors of the Nasal Cavity and Paranasal Sinuses: Clinical Outcomes and Patterns of Failure
Wiegner, E. A., Daly, M. E., Murphy, J. D., Abelson, J., Chapman, C. H., & Chang, D. T. (2012). Intensity-Modulated Radiotherapy for Tumors of the Nasal Cavity and Paranasal Sinuses: Clinical Outcomes and Patterns of Failure. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 83(1), 243-251.

A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
Padda, S. K., Krupitskaya, Y., Chhatwani, L., Fisher, G. A., Colevas, A. D., & Wakelee, H. A. (2012). A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 69(4), 1013-1020.

Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer
Riess, J. W., Logan, A. C., Krupitskaya, Y., Padda, S., Clement-Duchene, C., & Wakelee, H. A. (2012). Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer. CANCER INVESTIGATION, 30(3), 231-235.

Mucosal Melanoma of the Head and Neck
Pfister, D. G., Ang, K.-K., Brizel, D. M., Burtness, B., Cmelak, A. J., & Schuller, D. E. (2012). Mucosal Melanoma of the Head and Neck. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(3), 320-338.

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., & Levy, R. (2012). Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. JOURNAL OF CLINICAL INVESTIGATION, 122(3), 1066-1075.

Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial
Lee, N. Y., Zhang, Q., Pfister, D. G., Kim, J., Garden, A. S., & Ang, K. K. (2012). Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. LANCET ONCOLOGY, 13(2), 172-180.

The use of epidermal growth factor receptor monoclonal antibodies in squamous cell carcinoma of the head and neck.
Russell, J. S., & Colevas, A. D. (2012). The use of epidermal growth factor receptor monoclonal antibodies in squamous cell carcinoma of the head and neck. Chemotherapy research and practice, 2012, 761518-?.

Head and Neck Cancers
Pfister, D. G., Ang, K.-K., Brizel, D. M., Burtness, B. A., Cmelak, A. J., & Worden, F. (2011). Head and Neck Cancers. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(6), 596-649.

Controversies in the Locoregional Management of Head and Neck Cancer
Brizel, D. M., Lydiatt, W., & Colevas, A. D. (2011). Controversies in the Locoregional Management of Head and Neck Cancer. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(6), 653-662.

INTENSITY-MODULATED RADIOTHERAPY FOR LOCALLY ADVANCED CANCERS OF THE LARYNX AND HYPOPHARYNX
Daly, M. E., Le, Q.-T., Jain, A. K., Maxim, P. G., Hsu, A., & Chang, D. T. (2011). INTENSITY-MODULATED RADIOTHERAPY FOR LOCALLY ADVANCED CANCERS OF THE LARYNX AND HYPOPHARYNX. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 33(1), 103-111.

A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer
Clement-Duchene, C., Krupitskaya, Y., Ganjoo, K., Lavori, P., McMillan, A., & Wakelee, H. A. (2010). A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 5(11), 1821-1825.

HIGHER INCIDENCE OF HEAD AND NECK CANCERS AMONG VIETNAMESE AMERICAN MEN IN CALIFORNIA
Filion, E. J., McClure, L. A., Huang, D., Seng, K., Kaplan, M. J., & Le, Q.-T. (2010). HIGHER INCIDENCE OF HEAD AND NECK CANCERS AMONG VIETNAMESE AMERICAN MEN IN CALIFORNIA. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 32(10), 1336-1344.

MOLECULAR AND CLINICAL RESPONSES IN A PILOT STUDY OF GEFITINIB WITH PACLITAXEL AND RADIATION IN LOCALLY ADVANCED HEAD-AND-NECK CANCER
Van Waes, C., Allen, C. T., Citrin, D., Gius, D., Colevas, A. D., & Morris, J. C. (2010). MOLECULAR AND CLINICAL RESPONSES IN A PILOT STUDY OF GEFITINIB WITH PACLITAXEL AND RADIATION IN LOCALLY ADVANCED HEAD-AND-NECK CANCER. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 77(2), 447-454.

Excellent early local control with tumor volume adapted dosing of stereotactic body radiation therapy for pulmonary tumors
Chang, C. N., Zhou, L. Y., MacFarlane, G., Tran, P., Rao, A., & Loo, B. W. (2009). Excellent early local control with tumor volume adapted dosing of stereotactic body radiation therapy for pulmonary tumors. JOURNAL OF THORACIC ONCOLOGY, 4(9), S938-S939.

LONG-TERM OUTCOMES AND TOXICITY OF CONCURRENT PACLITAXEL AND RADIOTHERAPY FOR LOCALLY ADVANCED HEAD-AND-NECK CANCER
Citrin, D., Mansueti, J., Likhacheva, A., Sciuto, L., Albert, P. S., & Van Waes, C. (2009). LONG-TERM OUTCOMES AND TOXICITY OF CONCURRENT PACLITAXEL AND RADIOTHERAPY FOR LOCALLY ADVANCED HEAD-AND-NECK CANCER. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 74(4), 1040-1046.

Does Pre-treatment Metabolic Tumor Growth Rate (MTGR) Predict Progression in Lung Cancer?
Eastham, D. V., Chapman, C. H., Rao, A. K., Narasimhan, B., Quon, A., & Loo, B. W. (2009). Does Pre-treatment Metabolic Tumor Growth Rate (MTGR) Predict Progression in Lung Cancer?. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75(3), S446-S446.

A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma
O'Connor, O. A., Portlock, C., Moskowitz, C., Straus, D., Hamlin, P., & Zelenetz, A. (2008). A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma. BRITISH JOURNAL OF HAEMATOLOGY, 143(2), 201-209.

Head and neck cancers.
Forastiere, A. A., Ang, K.-K., Brizel, D., Brockstein, B. E., Burtness, B. A., & Worden, F. (2008). Head and neck cancers. Journal of the National Comprehensive Cancer Network , 6(7), 646-695.

Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck
Tang, P. A., Siu, L. L., Chen, E. X., Hotte, S. J., Chia, S., & Winquist, E. (2008). Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. INVESTIGATIONAL NEW DRUGS, 26(3), 257-264.

Patient-reported outcomes and the evolution of adverse event reporting in oncology
Trotti, A., Colevas, A. D., Setser, A., & Basch, E. (2007). Patient-reported outcomes and the evolution of adverse event reporting in oncology. JOURNAL OF CLINICAL ONCOLOGY, 25(32), 5121-5127.

Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer
Posner, M. R., Hershock, D. M., Blajman, C. R., Mickiewicz, E., Winquist, E., & Haddad, R. I. (2007). Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. NEW ENGLAND JOURNAL OF MEDICINE, 357(17), 1705-1715.

A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors
Hensley, M. L., Dizon, D., Derosa, F., Venkatraman, E., Sabbatini, P., & Aghajanian, C. (2007). A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors. INVESTIGATIONAL NEW DRUGS, 25(4), 335-341.

Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: A phase II trial in adults with poor-risk acute myelogenous leukemia
Karp, J. E., Smith, B. D., Levis, M. J., Gore, S. D., Greer, J., & Colevas, A. D. (2007). Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: A phase II trial in adults with poor-risk acute myelogenous leukemia. CLINICAL CANCER RESEARCH, 13(15), 4467-4473.

Inhibition of poly (ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models
Albert, J. M., Cao, C., Kim, K. W., Willey, C. D., Geng, L., & Lu, B. (2007). Inhibition of poly (ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. CLINICAL CANCER RESEARCH, 13(10), 3033-3042.

Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma
Nabors, L. B., Mikkelsen, T., Rosenfeld, S. S., Hochberg, F., Akella, N. S., & Grossman, S. A. (2007). Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. JOURNAL OF CLINICAL ONCOLOGY, 25(13), 1651-1657.

A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma
Posadas, E. M., Undevia, S., Manchen, E., Wade, J. L., Colevas, A. D., & Stadler, W. M. (2007). A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma. CANCER BIOLOGY & THERAPY, 6(4), 490-493.

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
Byrd, J. C., Lin, T. S., Dalton, J. T., Wu, D., Phelps, M. A., & Grever, M. R. (2007). Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. BLOOD, 109(2), 399-404.

Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours
Messersmith, W. A., Rudek, M. A., Baker, S. D., Zhao, M., Collins, C., & Wolff, A. C. (2007). Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours. EUROPEAN JOURNAL OF CANCER, 43(1), 78-86.

Adverse event reporting in publications compared with sponsor database for cancer clinical trials
Scharf, O., & Colevas, A. D. (2006). Adverse event reporting in publications compared with sponsor database for cancer clinical trials. JOURNAL OF CLINICAL ONCOLOGY, 24(24), 3933-3938.

Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck
Colevas, A. D. (2006). Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. JOURNAL OF CLINICAL ONCOLOGY, 24(17), 2644-2652.

Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: Scientific rationale and study design
Beekman, K. W., Colevas, A. D., Cooney, K., DiPaola, R., Dunn, R. L., & Hussain, M. (2006). Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: Scientific rationale and study design. CLINICAL GENITOURINARY CANCER, 4(4), 299-302.

In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent
Rudek, M. A., Zhao, M., Smith, N. F., Robey, R. W., He, P., & Baker, S. D. (2005). In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent. CLINICAL CANCER RESEARCH, 11(23), 8503-8511.

Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias
Karp, J. E., Passaniti, A., Gojo, I., Kaufmann, S., Bible, K., & Bauer, K. S. (2005). Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. CLINICAL CANCER RESEARCH, 11(23), 8403-8412.

Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: A southwest oncology group trial S0111
Hussain, M., Tangen, C. M., Lara, P. N., Vaishampayan, U. N., Petrylak, D. P., & Crawford, E. D. (2005). Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: A southwest oncology group trial S0111. JOURNAL OF CLINICAL ONCOLOGY, 23(34), 8724-8729.

Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma
Amrein, P. C., Clark, J. R., Supko, J. G., Fabian, R. L., Wang, C. C., & McIntyre, J. F. (2005). Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma. CANCER, 104(7), 1418-1427.

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer
Galsky, M. D., Small, E. J., Oh, W. K., Chen, I., Smith, D. C., & Kelly, W. K. (2005). Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. JOURNAL OF CLINICAL ONCOLOGY, 23(7), 1439-1446.

Current clinical trials of cilengitide, an alpha(v) antagonist in clinical development as an anticancer agent
Colevas, A. D., Scharf, O., & Schoenfeldt, M. (2004). Current clinical trials of cilengitide, an alpha(v) antagonist in clinical development as an anticancer agent. ONCOLOGY-NEW YORK, 18(14), 1778-?.

Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma
Burdette-Radoux, S., Tozer, R. G., Lohmann, R. C., Quirt, I., Ernst, D. S., & Eisenhauer, E. A. (2004). Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. INVESTIGATIONAL NEW DRUGS, 22(3), 315-322.

HER2 expression in salivary gland carcinomas: Dependence on histological subtype
Glisson, B., Colevas, A. D., Haddad, R., Krane, J., El-Naggar, A., & Posner, M. (2004). HER2 expression in salivary gland carcinomas: Dependence on histological subtype. CLINICAL CANCER RESEARCH, 10(3), 944-946.

Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study
Haddad, R., Colevas, A. D., Krane, J. F., Cooper, D., Glisson, B., & Posner, M. (2003). Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. ORAL ONCOLOGY, 39(7), 724-727.

CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment
Trotti, A., Colevas, A. D., SETSER, A., Rusch, V., Jaques, D., & Rubin, P. (2003). CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. SEMINARS IN RADIATION ONCOLOGY, 13(3), 176-181.

Development of investigational radiation modifiers
Colevas, A. D., Brown, J. M., Hahn, S., Mitchell, J., Camphausen, K., & Coleman, C. N. (2003). Development of investigational radiation modifiers. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 95(9), 646-651.

Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck - The Dana Farber Cancer Institute experience
Haddad, R., Colevas, A. D., Tishler, R., Busse, P., Goguen, L., & Posner, M. (2003). Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck - The Dana Farber Cancer Institute experience. CANCER, 97(2), 412-418.

Organ preservation-induction chemotherapy.
Colevas, A. D. (2003). Organ preservation-induction chemotherapy. Cancer treatment and research, 114, 213-234.

Timed sequential therapy of acute leukemia with flavopiridol: In vitro model for a phase I clinical trial
Karp, J. E., Ross, D. D., Yang, W. D., Tidwell, M. L., Wei, Y. T., & Colevas, A. D. (2003). Timed sequential therapy of acute leukemia with flavopiridol: In vitro model for a phase I clinical trial. CLINICAL CANCER RESEARCH, 9(1), 307-315.

A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck
Tishler, R. B., Norris, C. M., Colevas, A. D., Lamb, C. C., Karp, D., & Posner, M. R. (2002). A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. CANCER, 95(7), 1472-1481.

Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN)
Colevas, A. D., Norris, C. M., Tishler, R. B., Lamb, C. C., Fried, M. P., & Posner, M. R. (2002). Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN). AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 25(2), 153-159.

Hypothyroidism incidence after multimodality treatment for stage III and IV squamous cell carcinomas of the head and neck
Colevas, A. D., Read, R., Thornhill, J., Adak, S., Tishler, R., & Posner, M. (2001). Hypothyroidism incidence after multimodality treatment for stage III and IV squamous cell carcinomas of the head and neck. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 51(3), 599-604.

Clinical trials referral resource: Current clinical trials of epothilone B analog (BMS-247550)
Colevas, A. D., West, P. J., & Cheson, B. D. (2001). Clinical trials referral resource: Current clinical trials of epothilone B analog (BMS-247550). ONCOLOGY-NEW YORK, 15(9), 1168-?.

A Phase II study of combined oral uracil and ftorafur with leucovorin for patients with squamous cell carcinoma of the head and neck
Colevas, A. D., Amrein, P. C., Gomolin, H., Barton, J. J., Read, R. R., & Posner, M. R. (2001). A Phase II study of combined oral uracil and ftorafur with leucovorin for patients with squamous cell carcinoma of the head and neck. CANCER, 92(2), 326-331.

Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck
Posner, M. R., Glisson, B., Frenette, G., al-Sarraf, M., Colevas, A. D., & Garay, C. A. (2001). Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. JOURNAL OF CLINICAL ONCOLOGY, 19(4), 1096-1104.

NCCN Practice Guidelines for head and neck cancers
Forastiere, A. A., Pfister, D. G., Ang, K., Brockstein, B., Colevas, A. D., & Wolf, G. T. (2000). NCCN Practice Guidelines for head and neck cancers. ONCOLOGY-NEW YORK, 14(11A), 163-194.

The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck
Posner, M. R., Colevas, A. D., & Tishler, R. B. (2000). The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck. SEMINARS IN ONCOLOGY, 27(4), 13-24.

A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck
Colevas, A. D., Adak, S., Amrein, P. C., Barton, J. J., Costello, R., & Posner, M. R. (2000). A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck. ANNALS OF ONCOLOGY, 11(5), 535-539.

Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck
Colevas, A. D., Norris, C. M., Tishler, R. B., Fried, M. P., Gomolin, H. I., & Posner, M. R. (1999). Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. JOURNAL OF CLINICAL ONCOLOGY, 17(11), 3503-3511.

Re: "Sialadenosis: a presenting sign in Bulemia" (Head and Neck 20: 758-762, 1998)
Colevas, A. D. (1999). Re: "Sialadenosis: a presenting sign in Bulemia" (Head and Neck 20: 758-762, 1998). Head & neck, 21(6), 582-?.

An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies
Tishler, R. B., Busse, P. M., Norris, C. M., Rossi, R., Poulin, M., & Posner, M. R. (1999). An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 43(5), 1001-1008.

Intramucosal spread of malignant melanoma of the oral cavity
Bhattacharyya, N., Norris, C. M., Colevas, A. D., & Chasse, T. A. (1998). Intramucosal spread of malignant melanoma of the oral cavity. OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 119(6), 711-711.

Docetaxel in head and neck cancer - A review
Colevas, A. D., & Posner, M. R. (1998). Docetaxel in head and neck cancer - A review. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 21(5), 482-486.

Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: A phase I/II trial
Colevas, A. D., Busse, P. M., Norris, C. M., Fried, M., Tishler, R. B., & Posner, M. R. (1998). Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: A phase I/II trial. JOURNAL OF CLINICAL ONCOLOGY, 16(4), 1331-1339.

The Prognostic Value of Thymidylate Synthase and p53 Expression in Patients Treated with Induction Chemotherapy for Squamous Cell Carcinoma of the Head and Neck.
Posner, M. R., Johnston, P. G., Tishler, R. B., Andersen, J., Fiorentino, M., & Norris, C. M. (1998). The Prognostic Value of Thymidylate Synthase and p53 Expression in Patients Treated with Induction Chemotherapy for Squamous Cell Carcinoma of the Head and Neck. The oncologist, 3(6), 424-431.

Future directions in the treatment of squamous cell carcinoma of the head and neck: the role of UFT.
Colevas, A. D. (1997). Future directions in the treatment of squamous cell carcinoma of the head and neck: the role of UFT. Oncology (Williston Park, N.Y.), 11(9), 86-89.